Evaluation of Efficacy of X-Ray Alone and in Combination with Radiosensitizer in Subcutaneous and Intracranial Tumor Models

Author(s): Wentao Li, Xiaoyan He, Weiwei Cheng, Lingyun Zhang, Guannan Li, Linfeng Li, Qiuliang Li, Jing Jin, Yongfei Wang, Xuesong Ren, Zhi Wei, Long Shi, Yiran Wei, Wei Yun, Jingqi Huang

In this study, 13 tumor cell line derived subcutaneous models and one intracranial tumor model were evaluated by the application of X-ray radiation. The response of radiation levels on different tumor types and different tumor models were assessed by using the device (X-RAD225, Pxi precision, USA) delivering the targeted radiation directly on the focal tumor site. Furthermore, we investigated the combined benefits of radiation and a chemotherapy medication, Gemcitabine, on the H22 murine hepatic carcinoma cells derived subcutaneous syngeneic model. The impact of radiation treatment on the NCI-H1975-luc, human non-small cell lung cancer intracranial model in combination with Human checkpoint kinase ataxia telangiectasia-mutated (ATM) kinase inhibitor AZD0156 was studied. In addition, the integrity of the blood-brain barrier and the presence of the pharmacodynamic marker pRAD50 of AZD0156 were evaluated. The study outcome demonstrated that X-ray radiation has anti-tumor effects across all studied models, and also in combination treatment with radiosensitizer, Gemcitabine or AZD0156. We believe this study demonstrates there is a lot of potential fully utilizing radiation platform identifying radiation sensitizer or chemo candidates to benefit the management of oncology society.